^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Signatera™

    Company:
    Natera
    Type:
    CE Marked
    Related tests:
    7d
    ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer. (PubMed, Clin Cancer Res)
    ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patient with MIBC following TMT.
    Journal • Circulating tumor DNA
    |
    Signatera™
    12d
    ALTAIR: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection (clinicaltrials.gov)
    P3, N=243, Completed, National Cancer Center Hospital East | Recruiting --> Completed
    Trial completion • Circulating tumor DNA
    |
    Signatera™
    |
    Lonsurf (trifluridine/tipiracil)
    13d
    Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, University of Wisconsin, Madison | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date • Checkpoint inhibition • Circulating tumor DNA
    |
    Signatera™
    13d
    ULTIMATE: ctDNA-Informed Management of Early-Stage Rectal Cancer (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, University of California, Davis | Initiation date: Nov 2025 --> Mar 2026
    Trial initiation date • Circulating tumor DNA
    |
    Signatera™
    13d
    LBC-Monitor: Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Julia Foldi | Trial completion date: Oct 2026 --> Oct 2029 | Trial primary completion date: Oct 2026 --> Oct 2029
    Trial completion date • Trial primary completion date • Liquid biopsy • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Signatera™
    19d
    SIGNAL-EMC 101: Signatera Assessment in Early-Stage Endometrial Cancer (clinicaltrials.gov)
    P=N/A, N=1010, Not yet recruiting, Natera, Inc.
    New trial • Circulating tumor DNA
    |
    Signatera™
    20d
    Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease (clinicaltrials.gov)
    P1, N=32, Recruiting, Washington University School of Medicine | N=16 --> 32
    Enrollment change
    |
    Signatera™
    |
    Hiltonol (poly-ICLC)
    30d
    Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers. (PubMed, Cancer)
    ctDNA dynamics predicted progression and may guide treatment or imaging. ctDNA offers a minimally invasive, cost-effective adjunct to radiographic surveillance.
    Retrospective data • Journal • Circulating tumor DNA
    |
    Signatera™
    1m
    CaptAin: Effect of Capivasertib on ctDNA in ER Positive Breast Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Imperial College London | N=20 --> 0 | Trial completion date: Nov 2027 --> Sep 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Sep 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Circulating tumor DNA
    |
    Signatera™
    |
    Truqap (capivasertib)
    1m
    SIGNAL-ER 101: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer (clinicaltrials.gov)
    P=N/A, N=725, Not yet recruiting, Natera, Inc. | Phase classification: P2 --> P=N/A | Initiation date: Nov 2025 --> Mar 2026
    Phase classification • Trial initiation date
    |
    Signatera™
    2ms
    Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Natera Press Release)
    "Natera, Inc. (NASDAQ: NTRA)...today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year."
    New P3 trial
    |
    Signatera™
    2ms
    I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer (Natera Press Release)
    "Natera, Inc...together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications."
    Clinical
    |
    Signatera™